What a brutal six months it’s been for Enovis. The stock has dropped 22.5% and now trades at $31.96, rattling many shareholders. This might have investors contemplating their next move.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including STAAR Surgical (NASDAQ:STAA) and its peers.
Let’s dig into the relative performance of Integer Holdings (NYSE:ITGR) and its peers as we unravel the now-completed Q4 medical devices & supplies - specialty earnings season.
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 11.1%. This drop was worse than the S&P 500’s 4% loss.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQ:STAA) and the best and worst performers in the medical devices & supplies - specialty industry.
Medical technology company Enovis Corporation (NYSE:ENOV) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 23.3% year on year to $561 million. On the other hand, the company’s full-year revenue guidance of $2.21 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $0.98 per share was 7% above analysts’ consensus estimates.
JMP Securities initiates coverage on Enovis Corporation with a Market Outperform rating, highlighting its strategic acquisitions, including LimaCorporate, and future growth potential. The analyst notes the company's undervaluation and sees revenue catalysts ahead.
The medical info systems industry is thriving due to the growing demand for contactless services. Amid this environment, here are some stocks in the industry that may see stable returns in 2024.
Enovis reports Q4 results with net sales surging 11% YoY, reaching $455 million. The growth is attributed to strong performance in P&R and above-market expansion in Recon, coupled with recent acquisitions impact.
